Study guide
17.3 CAPA Implementation and Effectiveness Verification
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
17.3 CAPA Implementation and Effectiveness Verification
Key Takeaways Explain This Topic AI
An approved SOP demonstrates an implemented action, not necessarily effectiveness.
Effectiveness checks need relevant records, a defined measure and appropriate observation.
Retain superseded consent masters and executed records while removing obsolete blank forms from active use.
Last updated: October 2026
CAPA Implementation and Effectiveness Verification
A CAPA plan cannot be marked "closed" merely because the site drafted a revised SOP or held a training meeting. Under GCP quality principles, a CAPA is only successful if objective evidence proves that the remediation effectively prevented the failure mode from recurring.
Tip
During routine monitoring visits, the CRA conducts prospective effectiveness checks at predefined intervals—at trial-appropriate milestones; 30, 60 and 90 days are one illustrative schedule, not an ICH rule:
30-Day Check: The CRA verifies that the revised tool, SOP, or workflow is fully finalized, approved, and that all active site staff on the Delegation of Authority log have documented completion of training.
60-Day Check: The CRA audits a sample of newly generated source documents (e.g., the next 3 consecutively enrolled subjects or the next 5 clinical visit records) to verify that staff are actively executing the new procedure.
90-Day Check: The CRA performs a comprehensive data audit across the specific operational domain to confirm zero recurrences of the deviation. If non-compliance re-emerges, the CAPA has failed ; the CRA should reassess and escalate the issue, escalate to sponsor management, and initiate a secondary root cause analysis.
The CRA's Operational Role in Site RCA and CAPA Management
In the field, the CRA is the primary interface between the sponsor's quality organization and site clinical personnel. The CRA's duties include:
Facilitating Objective RCA: When a deviation is discovered, the CRA guides the Principal Investigator and study coordinator through structured inquiry (such as the 5 Whys), preventing the site from defaulting to defensive excuses or generic "retraining" promises.
Reviewing and Tracking Written CAPAs: The CRA inspects the site's written CAPA submission for completeness, ensuring it contains distinct containment, corrective action, and preventive action sections, accompanied by realistic completion milestones.
Tracking in Clinical Trial Management Systems (CTMS): The CRA logs the deviation and associated CAPA into the sponsor's CTMS and Site Issue Tracking Log, detailing the severity classification, root cause category, assigned owners, and target resolution dates.
Verifying Objective Evidence During Monitoring Visits: At every Interim Monitoring Visit (IMV), the CRA inspects primary physical proof—such as signed SOP revision logs, updated clinic worksheets, or newly calibrated equipment certificates—rather than accepting verbal assurances.
Escalation Management: If an investigator refuses to implement an agreed-upon CAPA, if deadlines are repeatedly breached, or if severe non-compliance recurs, the CRA must immediately escalate the finding to the Clinical Project Manager (CPM), Medical Monitor, and Sponsor Quality Assurance (QA). Persistent non-compliance may trigger formal sponsor audits, enrollment freezes, or site termination under ICH E6(R3).
Comparative Analysis: Containment vs. Corrective vs. Preventive Actions
The following matrix illustrates the clinical operational differences between the three tiers of remediation across realistic trial monitoring scenarios:
Clinical Trial Deviation Scenario Tier 1: Correction (Immediate Containment) Tier 2: Corrective Action (Prevent Site Recurrence) Tier 3: Preventive Action (Systemic / Cross-Trial Prevention)
Scenario A: Informed Consent Version Error: Subject 108 signed Version 2 of the ICF two weeks after Version 3 was approved by the IRB and released by the sponsor. Immediately re-consent Subject 108 using the approved Version 3 ICF; file a protocol deviation log entry. Remove obsolete blank Version 2 forms from active use while retaining superseded masters and all executed consent records; establish a mandatory site rule requiring coordinators to pull ICFs directly from the regulatory portal on the morning of each consent encounter. Institutional Review Board / Sponsor updates the electronic trial portal to automatically archive obsolete versions and send automated push notifications to all multi-center site coordinators when a new version is released.
Scenario B: Investigational Product Freezer Excursion: A -20°C research pharmacy freezer rose to -4°C over a holiday weekend due to a tripped circuit breaker. Immediately quarantine all impacted IP vials in a backup calibrated freezer; label vials "Do Not Dispense"; notify sponsor clinical supply manager for stability evaluation. Install a continuous automated temperature monitoring system connected to the hospital emergency backup power generator with an active 24/7 telephonic dialer alert. Sponsor QA audits pharmacy facilities across all participating trial sites to verify that continuous monitoring with emergency power backup is a mandatory site qualification prerequisite.
Scenario C: Missed Pharmacokinetic (PK) Blood Draws: Three consecutive subjects missed their mandatory 2-hour post-dose PK draws due to infusion suite staffing handoff delays. Obtain a late specimen if medically permissible per protocol; document the exact deviation timestamp in the source notes and laboratory requisition. Redesign the site's daily clinical scheduling template to assign a dedicated research nurse to each PK subject throughout the entire 4-hour post-dose window; implement a bedside timer alarm protocol. Sponsor Clinical Operations team amends the global trial protocol across all sites to expand the rigid ±5-minute PK collection window to an operationally feasible ±15-minute window based on pharmacokinetic modeling.
Scenario D: Ineligible Subject Enrollment: Subject 312 was randomized despite baseline serum potassium of 5.4 mEq/L (protocol exclusion threshold was >5.0 mEq/L). Immediately notify the Principal Investigator and Sponsor Medical Monitor; evaluate subject safety; discontinue study drug administration per protocol safety stopping rules. Implement a mandatory "Eligibility Sign-Off Worksheet" requiring the PI or Sub-I to physically initial and date every individual laboratory value against inclusion/exclusion criteria before randomization codes are requested. Sponsor updates the Interactive Response Technology (IRT) / EDC randomization module to require mandatory entry of baseline laboratory values, programming hard automated stops that block randomization if values exceed protocol cutoffs.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .